Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
about
Advances in targeted and immunobased therapies for colorectal cancer in the genomic eraOnto better TRAILs for cancer treatmentPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trialsApoptotic agentsTargeting the apoptosis pathway in hematologic malignanciesGetting TRAIL back on track for cancer therapyRole of nanotechnology and gene delivery systems in TRAIL-based therapiesGeneral Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMACGene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesEffect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysisIdentification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.[Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis].Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis.Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.The Roles of ROS and Caspases in TRAIL-Induced Apoptosis and Necroptosis in Human Pancreatic Cancer CellsAntiangiogenic variant of TSP-1 targets tumor cells in glioblastomas.On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells.Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.Clinical targeting of the TNF and TNFR superfamiliesTargeted therapies in non-small cell lung carcinoma: what have we achieved so far?TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapyTherapeutic applications of TRAIL receptor agonists in cancer and beyond.An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growthTargeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.
P2860
Q26751344-59126745-2718-4797-A189-2016A726A6E1Q26768160-5D618BE3-63BB-49BA-A817-69A65B8FDE9CQ26771601-BBA446FB-4C31-49CF-9BEC-BFAB30FEC53EQ26796456-0B8245D9-1BF7-45CE-9968-2D49CDE9E2D7Q27016160-C5CABAC0-5679-42F1-83FA-62A6F64229BFQ27024422-7098ACD3-AD56-4D34-AEB7-5CBE0B59D22BQ27027460-8176217B-CCCA-4EFD-B869-A343704EB7C7Q28076798-6E8C9C70-3022-4D34-9FD0-B6DD61279234Q28385542-60A7CA3E-3494-4920-8C13-18B56A4BDDEEQ28548165-30D55820-2E7D-4E3E-8170-DDA4A8DE64E7Q31060162-C83A0562-C93D-4B42-ACC9-FFBABC2B06FAQ33430200-4D844B4D-6571-408F-8390-89691F73EEE3Q33739941-58B06FC5-00E4-4411-A798-2C6D75F78A15Q34149887-565A44CB-3754-4A5F-9531-FB384C5E3ACFQ34557885-4EAAFFB0-EDD9-435A-98BE-C1E3FAB9EC06Q34593475-B6354684-F840-4211-B6AB-FFA42A009588Q34608366-08CAC6D5-CF06-4864-BB61-DE374742751CQ35158520-E0D7100F-FEBF-44CE-8DF8-4B97235F7DDCQ35183874-8C39B2D9-9557-4E95-8E77-6A5B9E9B4E9BQ35545472-4BBF6326-FEA2-4315-9B21-D76E8BFD86D5Q35590091-04606011-8710-4BF1-AB60-9FBF8B905AADQ35639178-698335BE-8C82-4E82-97BA-F89CC5BB5CC3Q35653261-D2575106-5A15-4467-B53E-344E73B421DBQ35853714-00078EB5-3AF6-479F-88A0-D2D75C268D98Q36218165-9D6A61FF-F1F8-45E5-9F5D-7E66AFA03C34Q36246491-EDBB4D6F-B643-4EBE-BFE2-10DBDACE1D05Q36370570-B784EDA8-6FB5-44D9-9D7D-F7A48B694B33Q36395984-83CA3B3E-32EA-4D86-80E6-22F34E45CA55Q36561621-358BD41F-40C5-4B06-AC00-FBD33E064105Q36762882-1B24ED55-C66B-4762-89F5-90A54AAF2631Q36999705-FDE80CD2-FF48-4D72-9202-DDE1A0D15D1EQ37012681-32656405-42EB-4714-BEEE-A1109C20504DQ37029804-99DA7A5C-6E7D-48BC-891D-7D7C131CE6EDQ37071019-79426E51-9471-4297-B4FA-FCA17AD7B66AQ37114025-642E86CA-058B-4244-A75C-47D524DA479EQ37141627-78A3735E-7F12-46DB-B6C5-6083971CC0ADQ37223809-5E245D44-93EA-437F-81F0-A509B4F0C3B2Q37246966-C41C333B-0846-4B0B-B083-ED1CBC348291Q37299291-A1E7B758-9716-4262-95DB-47920391BFCDQ37473651-87E89AC0-1EB5-4739-86F9-DCBAB4ED18F7
P2860
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Randomized phase II study of d ...... ed non-small-cell lung cancer.
@ast
Randomized phase II study of d ...... ed non-small-cell lung cancer.
@en
type
label
Randomized phase II study of d ...... ed non-small-cell lung cancer.
@ast
Randomized phase II study of d ...... ed non-small-cell lung cancer.
@en
prefLabel
Randomized phase II study of d ...... ed non-small-cell lung cancer.
@ast
Randomized phase II study of d ...... ed non-small-cell lung cancer.
@en
P2093
P356
P1476
Randomized phase II study of d ...... ed non-small-cell lung cancer.
@en
P2093
Avi Ashkenazi
Barna Szima
Dominic Smethurst
Erzsébet Juhász
Howard Stern
István Albert
Jean-Louis Pujol
Jerzy Kozielski
Lukas Amler
Nigel Baker
P304
P356
10.1200/JCO.2011.37.2623
P407
P577
2011-10-17T00:00:00Z